Published in Cardiovasc Res on June 01, 2005
Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res (2008) 3.16
IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol (2010) 2.99
Systemic delivery of microRNA-181b inhibits nuclear factor-κB activation, vascular inflammation, and atherosclerosis in apolipoprotein E-deficient mice. Circ Res (2013) 2.01
Atherosclerosis in ApoE-deficient mice progresses independently of the NLRP3 inflammasome. Cell Death Dis (2011) 1.58
Arterial Effects of Canakinumab in Patients With Atherosclerosis and Type 2 Diabetes or Glucose Intolerance. J Am Coll Cardiol (2016) 1.40
Fatty acid-induced mitochondrial uncoupling elicits inflammasome-independent IL-1α and sterile vascular inflammation in atherosclerosis. Nat Immunol (2013) 1.36
Pathogen-mediated inflammatory atherosclerosis is mediated in part via Toll-like receptor 2-induced inflammatory responses. J Innate Immun (2010) 1.21
Elevated plasma IL-37, IL-18, and IL-18BP concentrations in patients with acute coronary syndrome. Mediators Inflamm (2014) 1.10
Inflammasomes: sensors of metabolic stresses for vascular inflammation. Front Biosci (Landmark Ed) (2013) 1.09
The interleukin-1 receptor antagonist anakinra improves endothelial dysfunction in streptozotocin-induced diabetic rats. Cardiovasc Diabetol (2014) 1.02
Early hyperlipidemia promotes endothelial activation via a caspase-1-sirtuin 1 pathway. Arterioscler Thromb Vasc Biol (2015) 1.02
Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets. Cytokine Growth Factor Rev (2015) 1.00
VASCULAR INFLAMMATION AND ATHEROGENESIS ARE ACTIVATED VIA RECEPTORS FOR PAMPs AND SUPPRESSED BY REGULATORY T CELLS. Drug Discov Today Ther Strateg (2008) 0.98
A dominant negative form of the transcription factor c-Jun affects genes that have opposing effects on lipid homeostasis in mice. J Biol Chem (2007) 0.91
Moderate hypoxia potentiates interleukin-1β production in activated human macrophages. Circ Res (2014) 0.88
Inflammasomes in cardiovascular diseases. Am J Cardiovasc Dis (2011) 0.86
Contribution of vascular cell-derived cytokines to innate and inflammatory pathways in atherogenesis. J Cell Mol Med (2011) 0.86
The Expression of CD14(+)CD16(+) Monocyte Subpopulation in Coronary Heart Disease Patients with Blood Stasis Syndrome. Evid Based Complement Alternat Med (2013) 0.86
Marked acceleration of atherosclerosis after Lactobacillus casei-induced coronary arteritis in a mouse model of Kawasaki disease. Arterioscler Thromb Vasc Biol (2012) 0.84
Ethanol inhibits activation of NLRP3 and AIM2 inflammasomes in human macrophages--a novel anti-inflammatory action of alcohol. PLoS One (2013) 0.82
Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary Syndrome. J Am Heart Assoc (2015) 0.81
Interleukin-1 signaling pathway as a therapeutic target in transthyretin amyloidosis. Amyloid (2014) 0.81
Expression analysis of the TAB2 protein in adult mouse tissues. Inflamm Res (2007) 0.81
Maternal diet supplemented with methyl-donors protects against atherosclerosis in F1 ApoE(-/-) mice. PLoS One (2013) 0.80
Inflammation imaging of atherosclerosis in Apo-E-deficient mice using a (99m)Tc-labeled dual-domain cytokine ligand. Nucl Med Biol (2014) 0.79
Regulation of Nlrp3 inflammasome by dietary metabolites. Semin Immunol (2015) 0.78
Expanded network of inflammatory markers of atherogenesis: where are we now? Open Cardiovasc Med J (2010) 0.77
Shear-Sensitive Genes in Aortic Valve Endothelium. Antioxid Redox Signal (2016) 0.77
Ganoderma lucidum Polysaccharides Reduce Lipopolysaccharide-Induced Interleukin-1 β Expression in Cultured Smooth Muscle Cells and in Thoracic Aortas in Mice. Evid Based Complement Alternat Med (2014) 0.77
Impact of an interleukin-1 receptor antagonist and erythropoietin on experimental myocardial ischemia/reperfusion injury. ScientificWorldJournal (2012) 0.76
Kruppel-Like Factor 2-Mediated Suppression of MicroRNA-155 Reduces the Proinflammatory Activation of Macrophages. PLoS One (2015) 0.76
Requirement for protein kinase R in interleukin-1alpha-stimulated effects in cartilage. Biochem Pharmacol (2007) 0.76
Serum concentrations of MCP-1 and IL-6 in combination predict the presence of coronary artery disease and mortality in subjects undergoing coronary angiography. Mol Cell Biochem (2017) 0.75
The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE(-/-) Mice. Mediators Inflamm (2016) 0.75
Terminalia bellirica Extract Inhibits Low-Density Lipoprotein Oxidation and Macrophage Inflammatory Response in Vitro. Antioxidants (Basel) (2016) 0.75
Interleukin-1 beta, interferon-gamma, and tumor necrosis factor-alpha gene expression in peripheral blood mononuclear cells of patients with coronary artery disease. ARYA Atheroscler (2015) 0.75
Ultrasound Biomicroscopic Imaging for Interleukin-1 Receptor Antagonist-Inhibiting Atherosclerosis and Markers of Inflammation in Atherosclerotic Development in Apolipoprotein-E Knockout Mice. Tex Heart Inst J (2015) 0.75
IL-1β Inhibition in Cardiovascular Complications Associated to Diabetes Mellitus. Front Pharmacol (2017) 0.75
Per os colchicine administration in cholesterol fed rabbits: Triglycerides lowering effects without affecting atherosclerosis progress. Lipids Health Dis (2017) 0.75
The IL-1RI Co-Receptor TILRR (FREM1 Isoform 2) Controls Aberrant Inflammatory Responses and Development of Vascular Disease. JACC Basic Transl Sci (2017) 0.75
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis (2010) 10.03
Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55
IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev (2008) 4.68
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature (2005) 3.02
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
[Statin treatment in primary and secondary prevention--a statement]. Rev Med Suisse (2014) 2.55
Mechanotransduction, PROX1, and FOXC2 cooperate to control connexin37 and calcineurin during lymphatic-valve formation. Dev Cell (2012) 2.45
Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine (2007) 2.33
IL-36R ligands are potent regulators of dendritic and T cells. Blood (2011) 2.20
Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine (2011) 2.15
Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost (2009) 2.05
CD14 is an acute-phase protein. J Immunol (2004) 2.04
Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum (2009) 2.03
Inferior vena cava parameters predict re-admission in ischaemic heart failure. Eur J Clin Invest (2014) 2.01
Interleukin-33 is biologically active independently of caspase-1 cleavage. J Biol Chem (2009) 2.00
Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol (2006) 1.99
Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res (2003) 1.99
Leptin signaling deficiency impairs humoral and cellular immune responses and attenuates experimental arthritis. J Immunol (2002) 1.95
Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. Circulation (2004) 1.90
B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum (2007) 1.85
Enhanced Th1 and Th17 responses and arthritis severity in mice with a deficiency of myeloid cell-specific interleukin-1 receptor antagonist. Arthritis Rheum (2010) 1.81
EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis (2012) 1.78
IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin? J Clin Endocrinol Metab (2002) 1.74
Connexin37 protects against atherosclerosis by regulating monocyte adhesion. Nat Med (2006) 1.70
Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis (2011) 1.68
Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol (2011) 1.66
The specific role of chemokines in atherosclerosis. Thromb Haemost (2007) 1.62
Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum (2009) 1.58
Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study. Circulation (2012) 1.57
Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci (Lond) (2004) 1.56
Mutations in connexin genes and disease. Eur J Clin Invest (2010) 1.56
Do allelic variants of the connexin37 1019 gene polymorphism differentially predict for coronary artery disease and myocardial infarction? Atherosclerosis (2006) 1.51
Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol (2005) 1.49
Clinical experience with mycophenolate mofetil in systemic autoimmune conditions refractory to common immunosuppressive therapies. Swiss Med Wkly (2009) 1.48
Receptor activator of NF- κB ligand (RANKL) increases the release of neutrophil products associated with coronary vulnerability. Thromb Haemost (2011) 1.48
Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract Res Clin Rheumatol (2006) 1.46
Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. Rheumatol Int (2007) 1.45
The natural cardioprotective particle HDL modulates connexin43 gap junction channels. Cardiovasc Res (2011) 1.43
Recommendations for the use of ultrasound in rheumatoid arthritis: literature review and SONAR score experience. Swiss Med Wkly (2013) 1.41
Late cardiac tamponade after percutaneous closure of a patent foramen ovale. Eur J Echocardiogr (2005) 1.41
Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation (2009) 1.41
Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo. Circulation (2005) 1.40
Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J Biol Chem (2001) 1.39
[The management of osteoarticular problems by internal/general practitioners is inadequate. Is this a problem?]. Rev Med Suisse (2005) 1.39
Stairs instead of elevators at workplace: cardioprotective effects of a pragmatic intervention. Eur J Cardiovasc Prev Rehabil (2010) 1.33
Enhanced expression of the inorganic phosphate transporter Pit-1 is involved in BMP-2-induced matrix mineralization in osteoblast-like cells. J Bone Miner Res (2006) 1.33
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis (2012) 1.33
Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol (2012) 1.32
The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine (2008) 1.32
Specific role of interleukin-1 in hepatic neutrophil recruitment after ischemia/reperfusion. Am J Pathol (2002) 1.31
Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice. Circulation (2006) 1.31
A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice. Arterioscler Thromb Vasc Biol (2008) 1.30
Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position - 107, implicating the Sp1 transcription factor. Biochem J (2003) 1.30
CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. Am J Physiol Heart Circ Physiol (2008) 1.25
CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. J Mol Cell Cardiol (2009) 1.24
Hypoxic pulmonary vasoconstriction requires connexin 40-mediated endothelial signal conduction. J Clin Invest (2012) 1.24
Indirect effects of leptin receptor deficiency on lymphocyte populations and immune response in db/db mice. J Immunol (2006) 1.24
Systemic rheumatoid vasculitis: a review. Semin Arthritis Rheum (2006) 1.23
The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytes. Arthritis Res Ther (2006) 1.23
IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells. Blood (2012) 1.23
The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study. Arthritis Rheum (2006) 1.23
Reduced connexin43 expression inhibits atherosclerotic lesion formation in low-density lipoprotein receptor-deficient mice. Circulation (2003) 1.22
Connexins in vascular physiology and pathology. Antioxid Redox Signal (2009) 1.22
Toward immunomodulatory and anti-inflammatory properties of statins. Trends Cardiovasc Med (2005) 1.22
Altered pattern of vascular connexin expression in atherosclerotic plaques. Arterioscler Thromb Vasc Biol (2002) 1.21
A DNA resequencing array for pathogenic mutation detection in hypertrophic cardiomyopathy. Hum Mutat (2008) 1.21
Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice. J Mol Cell Cardiol (2009) 1.20
Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis (2006) 1.19
Gap junctional communication in tissue inflammation and repair. Biochim Biophys Acta (2004) 1.19
Interleukin-1 and transforming growth factor-beta 1 as crucial factors in osteoarthritic cartilage metabolism. Connect Tissue Res (2008) 1.18
Dietary phytoestrogens activate AMP-activated protein kinase with improvement in lipid and glucose metabolism. Diabetes (2008) 1.17
Tumor necrosis factor-alpha (TNF-alpha) induces integrin CD11b/CD18 (Mac-1) up-regulation and migration to the CC chemokine CCL3 (MIP-1alpha) on human neutrophils through defined signalling pathways. Cell Signal (2007) 1.16
Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Res Ther (2014) 1.15
Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. Joint Bone Spine (2009) 1.15
The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation. Vitam Horm (2006) 1.14
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis (2011) 1.14
The inflammatory response as a target to reduce myocardial ischaemia and reperfusion injury. Thromb Haemost (2009) 1.14
Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis (2012) 1.13
CC and CXC chemokines are pivotal mediators of cerebral injury in ischaemic stroke. Thromb Haemost (2010) 1.13
Potential antiinflammatory and immunomodulatory effects of statins in rheumatologic therapy. Arthritis Rheum (2006) 1.13
Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. Arthritis Rheum (2007) 1.13